Rockwell Medical (RMTI) Scheduled to Post Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Rockwell Medical has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. Rockwell Medical had a negative net margin of 9.72% and a negative return on equity of 28.29%. The company had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $21.18 million. During the same quarter in the prior year, the company earned ($0.10) earnings per share. On average, analysts expect Rockwell Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rockwell Medical Trading Up 2.3 %

Shares of NASDAQ:RMTI opened at $1.77 on Wednesday. The firm has a market cap of $53.67 million, a price-to-earnings ratio of -4.92 and a beta of 1.43. The company has a quick ratio of 1.38, a current ratio of 1.79 and a debt-to-equity ratio of 0.47. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $3.16. The company’s fifty day simple moving average is $1.85 and its 200 day simple moving average is $1.63.

Analysts Set New Price Targets

Several research firms have recently weighed in on RMTI. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Rockwell Medical in a research report on Thursday, May 16th. StockNews.com raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, June 19th.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.